Newsroom: Confluent Announces Significant Investment in ATI Nitinol Melt Expansion

NDC Raises Growth Capital from Ampersand

Fremont, CA – April 25th, 2011 – Nitinol Devices & Components (NDC), a pioneer in Nitinol materials and manufacturing processes for the medical, industrial and consumer markets, has closed a $20 million growth equity financing with Ampersand Capital Partners (Ampersand). Terms of the transaction were not disclosed.

Since 1991, NDC’s engineers and scientists have designed and developed some of the world’s most successful Nitinol devices. NDC has unmatched Nitinol knowledge and experience, from providing highest purity Nitinol materials that are produced to the most stringent mechanical specifications, to manufacturing the most delicate and intricate implantable Nitinol devices and components on the market.

According to Tom Duerig, President and CEO of NDC, “Ampersand’s combined focus on materials science leadership and medical device outsourcing made them the logical choice to be NDC’s financial partner. Our working relationships with two of Ampersand’s other device outsourcing portfolio companies also helped to make us very comfortable partnering with Ampersand as our sole institutional investor.”

“We welcome the opportunity to collaborate with this exceptional management team, and we look forward to helping the company continue its impressive record of growth and achievement” said Rick Charpie, Founder and Managing Partner of Ampersand. “NDC fits squarely into our middle market growth investment profile. The company is a leader in the markets it serves, and is well positioned to capitalize on future acquisition and organic growth opportunities.”

As a result of this investment, Ampersand Partners Jared Bartok and Rick Charpie have joined the board of NDC.

About NDC
NDC is a privately held medical device company headquartered in Fremont, CA, USA. Focused on the medical field, NDC provides manufacturing, research, development, regulatory and technical support on all aspects of Nitinol technology and processing, and is aggressively expanding its capabilities to meet the growing demand for its shape-memory and superelastic Nitinol products. For more information:

About Ampersand
Ampersand is a middle market private equity firm with a focus in two core Sectors: Healthcare and Industrial. Within this core, Ampersand targets growth equity opportunities where it can be the first institutional investor. Ampersand’s unique blend of private equity and operating skills positions the firm to build value and drive long-term performance by working in support of the portfolio company management teams. For more information:


Latest News

March 8, 2024

Confluent Appoints Sandy Stojkovski and Brian Yoor to its Board of Directors

Read More ›
January 25, 2024

Confluent Announces Significant Investment in ATI Nitinol Melt Expansion

Read More ›
June 23, 2023

Confluent’s New Polymer Webshop Provides Solution to PTFE Lead Time Constraints

Read More ›

Partnering with you every step of the way

Contact Confluent Medical today and make sure your project is supported by our unmatched resources, technical expertise and proven service to meet any design, modification or manufacturing requirements.